These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33769179)

  • 1. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
    Braunstein M; Weltz J; Davies F
    Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
    Xia J; Li Z; Xu K
    J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T Therapy in Relapsed Refractory Multiple Myeloma.
    Ding H; Wu Y
    Curr Med Chem; 2024; 31(27):4362-4382. PubMed ID: 37779413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
    Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
    Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Based Treatment Approaches in Multiple Myeloma.
    Hosoya H; Sidana S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
    Tanenbaum B; Miett T; Patel SA
    Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
    Cho SF; Xing L; Anderson KC; Tai YT
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies and bispecifics for multiple myeloma: effective effector therapy.
    Cipkar C; Chen C; Trudel S
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):163-172. PubMed ID: 36485135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.